News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
The new centre will comprise a team of 50 highly experienced specialists
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
Subscribe To Our Newsletter & Stay Updated
